vs
Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and Crexendo, Inc. (CXDO). Click either name above to swap in a different company.
Crexendo, Inc. is the larger business by last-quarter revenue ($18.1M vs $10.7M, roughly 1.7× Arbutus Biopharma Corp). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 6.7%, a 16.7% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 11.2%). Over the past eight quarters, Crexendo, Inc.'s revenue compounded faster (12.4% CAGR vs -13.2%).
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Crexendo, Inc. is a U.S.-headquartered cloud communications technology provider. It delivers unified communications as a service (UCaaS), contact center solutions, business VoIP services, and collaborative work tools, primarily catering to small and medium-sized enterprises operating in the North American market.
ABUS vs CXDO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.7M | $18.1M |
| Net Profit | $2.5M | $1.2M |
| Gross Margin | — | — |
| Operating Margin | 13.9% | 6.3% |
| Net Margin | 23.5% | 6.7% |
| Revenue YoY | 522.2% | 11.2% |
| Net Profit YoY | 112.7% | 140.2% |
| EPS (diluted) | $0.01 | $0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $18.1M | ||
| Q3 25 | — | $17.5M | ||
| Q2 25 | $10.7M | $16.6M | ||
| Q1 25 | — | $16.1M | ||
| Q4 24 | — | $16.2M | ||
| Q3 24 | — | $15.6M | ||
| Q2 24 | — | $14.7M | ||
| Q1 24 | — | $14.3M |
| Q4 25 | — | $1.2M | ||
| Q3 25 | — | $1.4M | ||
| Q2 25 | $2.5M | $1.2M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $507.0K | ||
| Q3 24 | — | $148.0K | ||
| Q2 24 | — | $588.0K | ||
| Q1 24 | — | $434.0K |
| Q4 25 | — | 6.3% | ||
| Q3 25 | — | 7.5% | ||
| Q2 25 | 13.9% | 6.7% | ||
| Q1 25 | — | 7.2% | ||
| Q4 24 | — | 3.9% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 3.9% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 8.3% | ||
| Q2 25 | 23.5% | 7.4% | ||
| Q1 25 | — | 7.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | 3.0% |
| Q4 25 | — | $0.03 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | $0.01 | $0.04 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $0.03 | ||
| Q3 24 | — | $0.00 | ||
| Q2 24 | — | $0.02 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | — |
| Total DebtLower is stronger | $0 | $114.0K |
| Stockholders' EquityBook value | $83.0M | $63.8M |
| Total Assets | $103.3M | $77.7M |
| Debt / EquityLower = less leverage | 0.00× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $37.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $114.0K | ||
| Q3 25 | — | $236.0K | ||
| Q2 25 | $0 | $356.0K | ||
| Q1 25 | — | $475.0K | ||
| Q4 24 | — | $592.0K | ||
| Q3 24 | — | $709.0K | ||
| Q2 24 | — | $823.0K | ||
| Q1 24 | — | $937.0K |
| Q4 25 | — | $63.8M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | $83.0M | $58.3M | ||
| Q1 25 | — | $55.2M | ||
| Q4 24 | — | $51.4M | ||
| Q3 24 | — | $49.5M | ||
| Q2 24 | — | $48.2M | ||
| Q1 24 | — | $46.8M |
| Q4 25 | — | $77.7M | ||
| Q3 25 | — | $76.0M | ||
| Q2 25 | $103.3M | $71.4M | ||
| Q1 25 | — | $67.4M | ||
| Q4 24 | — | $64.9M | ||
| Q3 24 | — | $62.3M | ||
| Q2 24 | — | $59.6M | ||
| Q1 24 | — | $57.5M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | 0.00× | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $2.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | -6.24× | 1.93× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.3M | ||
| Q3 25 | — | $4.4M | ||
| Q2 25 | $-15.7M | $1.3M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | — | $1.6M | ||
| Q2 24 | — | $2.7M | ||
| Q1 24 | — | $-166.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $2.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 7.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 13.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.05× | ||
| Q2 25 | -6.24× | 1.05× | ||
| Q1 25 | — | 1.06× | ||
| Q4 24 | — | 4.29× | ||
| Q3 24 | — | 10.95× | ||
| Q2 24 | — | 4.51× | ||
| Q1 24 | — | -0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABUS
Segment breakdown not available.
CXDO
| Services | $8.6M | 48% |
| Software Solution Segment | $8.3M | 46% |
| Products | $1.1M | 6% |
